 <h1>Vytorin Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>ezetimibe / simvastatin</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about ezetimibe / simvastatin. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Vytorin.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to ezetimibe / simvastatin: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, ezetimibe/simvastatin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking ezetimibe / simvastatin:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Bloating</li>
<li>chills</li>
<li>constipation</li>
<li>darkened urine</li>
<li>fast heartbeat</li>
<li>fever</li>
<li>hives, itching, skin rash</li>
<li>hoarseness</li>
<li>indigestion</li>
<li>joint pain</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>loss of appetite</li>
<li>nausea</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>redness of the skin</li>
<li>stiffness</li>
<li>stomach fullness</li>
<li>swelling of the eyelids, face, lips, hands, or feet</li>
<li>tightness in the chest</li>
<li>trouble breathing or swallowing</li>
<li>vomiting</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of ezetimibe / simvastatin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Body aches or pain</li>
<li>cough</li>
<li>diarrhea</li>
<li>difficulty with moving</li>
<li>ear congestion</li>
<li>general feeling of discomfort or illness</li>
<li>headache</li>
<li>loss of voice</li>
<li>muscle aches and pains or cramping</li>
<li>muscle stiffness</li>
<li>pain in the arms or legs</li>
<li>runny or stuffy nose</li>
<li>shivering</li>
<li>sneezing</li>
<li>sore throat</li>
<li>sweating</li>
<li>swollen joints</li>
<li>trouble sleeping</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ezetimibe / simvastatin: oral tablet</i></p><h3>General</h3><p>The more commonly reported adverse effects have included headache, increased ALT, myalgia, upper respiratory tract infection, and diarrhea.</p><h3>Gastrointestinal</h3><p>Ezetimibe-simvastatin: </p>
<p><b>Common</b> (1% to 10%): Diarrhea</p>
<p></p>
<p>Ezetimibe:</p>
<p><b>Common</b> (1% to 10%): Diarrhea, abdominal pain, nausea</p>
<p><b>Postmarketing reports</b>: Pancreatitis</p>
<p></p>
<p>Simvastatin:</p>
<p><b>Common</b> (1% to 10%): Constipation, nausea, flatulence, diarrhea, dyspepsia, abdominal pain, pancreatitis, anorexia, vomiting, gastritis</p>
<p><b>Very rare</b> (less than 0.01%): Protein losing enteropathy<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Simvastatin has been associated with rare cases of severe myopathy and rhabdomyolysis.  This is accompanied by elevations in creatine kinase, myoglobinuria, and proteinuria, as well as renal failure.  Experience with HMG-CoA reductase inhibitors indicates that concomitant use with gemfibrozil, niacin, cyclosporine, or erythromycin may increase the incidence and the severity of musculoskeletal side effects.</p>
<p></p>
<p>A case of spontaneous biceps tendon rupture developed in a patient after 4 months of treatment with ezetimibe-simvastatin.  Upon rechallenge 2 months later, the patient developed pain in the contralateral arm overlying the biceps tendon.  Following discontinuation of ezetimibe-simvastatin, pain resolved 2 weeks later.  Inhibition of matrix metalloproteinases has been suggested as the contributing factor in the development of tendon rupture.<sup>[Ref]</sup></p><p>Ezetimibe-simvastatin: </p>
<p><b>Common</b> (1% to 10%): Myalgia, extremity pain </p>
<p><b>Very rare</b> (less than 0.01%): Tendon rupture (one case)</p>
<p><b>Frequency not reported</b>: Back pain </p>
<p><b>Postmarketing reports</b>: Muscle cramps </p>
<p></p>
<p>Ezetimibe:</p>
<p><b>Common</b> (1% to 10%): Back pain, arthralgia</p>
<p><b>Postmarketing reports</b>: Myalgia, elevated creatine phosphokinase, rare reports of myopathy/rhabdomyolysis</p>
<p></p>
<p>Simvastatin:</p>
<p><b>Uncommon</b> (0.1% to 1%): Myopathy, rhabdomyolysis </p>
<p><b>Frequency not reported</b>: Elevations in creatine kinase, dermatomyositis, arthralgia, myalgia<sup>[Ref]</sup></p><h3>Renal</h3><p>Simvastatin:</p>
<p><b>Frequency not reported</b>: Myoglobinuria, acute renal failure secondary to rhabdomyolysis<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Persistent elevations in liver function tests three times normal values are reported in up to 1.5% of patients on simvastatin in clinical trials.  In one study, this led to the discontinuation of simvastatin in 0.6% of patients.  In other patients, elevations in liver function tests were transient and returned to normal with continued simvastatin therapy.<sup>[Ref]</sup></p><p>Ezetimibe-simvastatin: </p>
<p><b>Common</b> (1% to 10%): Increased ALT</p>
<p><b>Frequency not reported</b>: Increased AST</p>
<p></p>
<p>Ezetimibe:</p>
<p><b>Postmarketing reports</b>: Elevations in liver transaminases, hepatitis, cholelithiasis, cholecystitis</p>
<p></p>
<p>Simvastatin:</p>
<p><b>Common</b> (1% to 10%): Elevations in liver function tests</p>
<p><b>Frequency not reported</b>: Hepatitis (including chronic active hepatitis), cholestatic jaundice, fatty changes in the liver, cirrhosis, fulminant hepatic necrosis </p>
<p><b>Postmarketing reports</b>: Hepatic failure, jaundice<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Simvastatin:</p>
<p><b>Frequency not reported</b>: Eczematous, pruritic rash, toxic epidermal necrolysis, photosensitivity, purpura, erythema multiforme, photosensitivity, purpura, alopecia</p>
<p><b>Postmarketing reports</b>: A variety of skin changes (e.g., nodules, discoloration, dryness of skin/mucous membranes, changes to hair/nails)<sup>[Ref]</sup></p><h3>Immunologic</h3><p>Ezetimibe-simvastatin: </p>
<p><b>Frequency not reported</b>: Influenza</p>
<p></p>
<p>Ezetimibe:</p>
<p><b>Common</b> (1% to 10%): Viral infection</p>
<p></p>
<p>Simvastatin:</p>
<p><b>Very rare</b> (less than 0.01%): Lupus-like syndrome</p>
<p><b>Frequency not reported</b>: Positive ANA, ESR increase, polymyalgia rheumatica, vasculitis</p>
<p></p>
<p>Statin use: </p>
<p><b>Rare</b> (0.01% to 0.1%): Immune-mediated necrotizing myopathy (IMNM)<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Ezetimibe-simvastatin: </p>
<p><b>Common</b> (1% to 10%): Upper respiratory tract infection</p>
<p><b>Frequency not reported</b>: Interstitial lung disease causing breathing problems including persistent cough and/or shortness of breath or fever</p>
<p></p>
<p>Ezetimibe:</p>
<p><b>Common</b> (1% to 10%): Coughing</p>
<p><b>Frequency not reported</b>: Sinusitis </p>
<p></p>
<p>Simvastatin:</p>
<p><b>Frequency not reported</b>: Sinusitis, pharyngitis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Simvastatin:</p>
<p><b>Common</b> (1% to 10%): Angina</p>
<p><b>Frequency not reported</b>: Atrial fibrillation, edema<sup>[Ref]</sup></p><h3>Endocrine</h3><p>Simvastatin:</p>
<p><b>Frequency not reported</b>: Gynecomastia, thyroid function abnormalities<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Simvastatin:</p>
<p><b>Frequency not reported</b>: Erectile dysfunction, impotence, urinary tract infections<sup>[Ref]</sup></p><h3>Hematologic</h3><p>A 65-year-old male with hereditary hemorrhagic telangiectasia (HHT) who had a history of minimal epistaxis began to experience profuse epistaxis 8 to 10 weeks after starting ezetimibe-simvastatin, The patient had been treated with simvastatin 20 mg alone for 9 years without any adverse effects.  Two months after starting combination therapy with ezetimibe-simvastatin he noticed epistaxis that increased from a few drops every other day to profuse bleeding for 20 to 30 minutes daily.  The patient reported initiation of ezetimibe-simvastatin as the only change in his treatment regimen in the past year.  When he stopped ezetimibe-simvastatin, his epistaxis decreased.  After six weeks without ezetimibe-simvastatin, he had only one moderate nose bleed.  Four months later, the patient's hemoglobin was stable.  He then started simvastatin 40 mg monotherapy.  The profound epistaxis returned and the patient discontinued the medication.  It remains unclear whether the patient's accelerated epistaxis was due to the combination therapy or the double dosage of simvastatin.<sup>[Ref]</sup></p><p>Ezetimibe-simvastatin: </p>
<p><b>Postmarketing reports</b>: Epistaxis (one report), anemia </p>
<p></p>
<p>Ezetimibe:</p>
<p><b>Postmarketing reports</b>: Thrombocytopenia</p>
<p></p>
<p>Simvastatin:</p>
<p><b>Frequency not reported</b>: Hemolytic anemia, thrombocytopenia, leukopenia (possibly manifestations of a hypersensitivity reaction)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria have been reported.  In addition, an apparent hypersensitivity syndrome has been reported rarely that has included one or more of the following features: anaphylaxis, angioedema, lupus erythematous-like syndrome, polymyalgia rheumatica, dermatomyositis, vasculitis, purpura, thrombocytopenia, leukopenia, hemolytic anemia, positive ANA, ESR increase, eosinophilia, arthritis, arthralgia, urticaria, asthenia, photosensitivity, fever, chills, flushing, malaise, dyspnea, toxic epidermal necrolysis, erythema multiforme, including Stevens-Johnson syndrome.<sup>[Ref]</sup></p><p>Ezetimibe:</p>
<p><b>Postmarketing reports</b>: Angioedema, anaphylaxis, rash, urticaria</p>
<p></p>
<p>Simvastatin:</p>
<p><b>Rare</b> (less than 0.1%): Erythema multiforme, Stevens-Johnson syndrome, anaphylaxis, angioedema, urticaria, fever, chills, flushing, malaise, dyspnea</p>
<p><b>Postmarketing reports</b>: Hypersensitivity reactions<sup>[Ref]</sup></p><h3>Nervous system</h3><p>A case of memory loss possibly related to simvastatin use has been reported.  The patient developed gradual memory loss following 12 months of simvastatin therapy.  He was switched to pravastatin, and within a month his memory was intact.  Rechallenge with simvastatin was not performed.</p>
<p></p>
<p>There have been rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use.  These reports have been generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).<sup>[Ref]</sup></p><p>Ezetimibe-simvastatin: </p>
<p><b>Common</b> (1% to 10%): Headache</p>
<p><b>Frequency not reported</b>: Confusion, fatigue</p>
<p></p>
<p>Ezetimibe:</p>
<p><b>Postmarketing reports</b>: Dizziness, paraesthesia</p>
<p></p>
<p>Simvastatin:</p>
<p><b>Frequency not reported</b>: Cranial nerve dysfunction, tremor, vertigo, memory loss, paraesthesias, peripheral neuropathy, peripheral nerve palsy</p>
<p></p>
<p>Statins: </p>
<p><b>Postmarketing reports</b>: Cognitive impairment<sup>[Ref]</sup></p><h3>Ocular</h3><p>Simvastatin:</p>
<p><b>Frequency not reported</b>: Progression of cataracts, ophthalmoplegia<sup>[Ref]</sup></p><h3>Oncologic</h3><p>Simvastatin:</p>
<p><b>Frequency not reported</b>: Liver, thyroid, and lung adenomas and carcinomas<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Simvastatin:</p>
<p><b>Frequency not reported</b>: Depression, suicidal thoughts, delusions, paranoia, agitation, decreased libido, anxiety, insomnia<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Simvastatin: </p>
<p><b>Frequency not reported</b>: Increases in HbA1c and fasting serum glucose levels</p><h3>Other</h3><p>Ezetimibe: </p>
<p><b>Frequency not reported</b>: Fatigue, asthenia<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Plosker GL, Mctavish D "Simvastatin - a reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia." Drugs 50 (1995): 334-63</p><p id="ref_2">2. Abernethy DR, Greenblatt DJ, Morse DS, Shader RI "Interaction of propoxyphene with diazepam, alprazolam and lorazepam." Br J Clin Pharmacol 19 (1985): 51-7</p><p id="ref_3">3. Chagnon JP, Cerf M "Simvastatin-induced protein-losing enteropathy." Am J Gastroenterol 87 (1992): 257</p><p id="ref_4">4. Simons LA "Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. The Principal Investigators." Clin Cardiol 16 (1993): 317-22</p><p id="ref_5">5. "Product Information. Zocor (simvastatin)." Merck &amp; Co, Inc, West Point, PA. </p><p id="ref_6">6. Walker JF "Simvastatin: the clinical profile." Am J Med 87 (1989): s44-6</p><p id="ref_7">7. "Product Information. Vytorin (ezetimibe-simvastatin)." Merck &amp; Company Inc, West Point, PA. </p><p id="ref_8">8. "Product Information. Zetia (ezetimibe)." Schering-Plough Corporation, Kenilworth, NJ. </p><p id="ref_9">9. Federman DG,  Hussain F,  Walters AB "Fatal rhabdomyolysis caused by lipid-lowering therapy." South Med J 94 (2001): 1023-6</p><p id="ref_10">10. Itakura H,  Vaughn D,  Haller DG,  O'Dwyer PJ "Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer." J Urol 169 (2003): 613</p><p id="ref_11">11. Weise WJ, Possidente CJ "Fatal rhabdomyolysis associated with simvastatin in a renal transplant patient." Am J Med 108 (2000): 351-2</p><p id="ref_12">12. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H "HMG-CoA reductase inhibitors and the risk of fractures." JAMA 283 (2000): 3205-10</p><p id="ref_13">13. Sinzinger H,  Wolfram R,  Peskar BA "Muscular side effects of statins." J Cardiovasc Pharmacol 40 (2002): 163-71</p><p id="ref_14">14. Davidson MH,  Maccubbin D,  Stepanavage M,  Strony J,  Musliner T "Striated muscle safety of ezetimibe / simvastatin (vytorin)." Am J Cardiol 97 (2006): 223-8</p><p id="ref_15">15. Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, Miettinen T, Musliner TA, Olsson AG, Pyorala K, Thorgeirsso "Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the scandinavian simvastatin survival study." Arch Intern Med 156 (1996): 2085-92</p><p id="ref_16">16. Schumacher YO,  Zdebik A,  Huonker M,  Kreisel W "Sildenafil in HIV-related pulmonary hypertension." AIDS 15 (2001): 1747-8</p><p id="ref_17">17. McDonagh J, Winocour P, Walker DJ "Musculoskeletal manifestations during simvastatin therapy." Br J Rheumatol 32 (1993): 647-8</p><p id="ref_18">18. Peces R,  Pobes A "Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem." Nephron 89 (2001): 117-8</p><p id="ref_19">19. Chan MH,  Mak TW,  Chiu RW,  Chow CC,  Chan IH,  Lam CW "Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia." J Clin Endocrinol Metab 86 (2001): 4556-9</p><p id="ref_20">20. Maxa JL,  Melton LB,  Ogu CC,  Sills MN,  Limanni A "Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole." Ann Pharmacother 36 (2002): 820-3</p><p id="ref_21">21. Pullatt RC,  Gadarla MR,  Karas RH,  Alsheikh-Ali AA,  Thompson PD "Tendon rupture associated with simvastatin/ezetimibe therapy." Am J Cardiol 100 (2007): 152-3</p><p id="ref_22">22. Alvarez JM, Rawdanowiz TJ, Goldstein J "Rhadbdomyolysis after coronary artery bypass grafting in a patient receiving simvastatin." J Thorac Cardiovasc Surg 116 (1998): 654-5</p><p id="ref_23">23. "Summaries for patients. Muscle abnormalities in four patients taking statins to treat unfavorable cholesterol levels." Ann Intern Med 137 (2002): I45</p><p id="ref_24">24. Khattak FH, Morris IM, Branford WA "Simvastatin-associated dermatomyositis." Br J Rheumatol 33 (1994): 199</p><p id="ref_25">25. Omar MA,  Wilson JP "FDA adverse event reports on statin-associated rhabdomyolysis." Ann Pharmacother 36 (2002): 288-95</p><p id="ref_26">26. van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996): 403-4</p><p id="ref_27">27. Vanpuijenbroek EP, Dubufvereijken PWG, Spooren PFMJ, Vandoormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996): 403-4</p><p id="ref_28">28. Havranek JM,  Wolfsen AR,  Warnke GA,  Phillips PS "Monotherapy with ezetimibe causing myopathy." Am J Med 119 (2006): 285-6</p><p id="ref_29">29. Chariot P, Abadia R, Agnus D, Danan C, Charpentier C, Gherardi RK "Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome." Am J Med 94 (1993): 109-10</p><p id="ref_30">30. ChoquetKastylevsky G, Kanitakis J, Dumas V, Descotes J, Faure M, Claudy A "Eosinophilic fasciitis and simvastatin." Arch Intern Med 161 (2001): 1456-7</p><p id="ref_31">31. Grundy SM "Can statins cause chronic low-grade myopathy?" Ann Intern Med 137 (2002): 617-8</p><p id="ref_32">32. Yurdakok M, Gurakan B, Ergin H, Kirazli S "Plasma concentrations of granulocyte colony stimulating factor in preterm infants in the first few hours of life." Acta Paediatr 85 (1996): 1389-90</p><p id="ref_33">33. Mauro VF, MacDonald JL "Simvastatin: a review of its pharmacology and clinical use." DICP 25 (1991): 257-64</p><p id="ref_34">34. Nakad A, Bataille L, Hamoir V, Sempoux C, Horsmans Y "Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin." Lancet 353 (1999): 1763-4</p><p id="ref_35">35. Krasovec M, Elsner P, Burg G "Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors." Dermatology 186 (1993): 248-52</p><p id="ref_36">36. Feldmann R, Mainetti C, Saurat JH "Skin lesions due to treatment with simvastatin (Zocor)." Dermatology 186 (1993): 272</p><p id="ref_37">37. Rudski L, Rabinovitch MA, Danoff D "Systemic immune reactions to HMG-CoA reductase inhibitors - Report of 4 cases and review of the literature." Medicine 77 (1998): 378-83</p><p id="ref_38">38. Bannwarth B, Miremont G, Papapietro PM "Lupuslike syndrome associated with simvastatin." Arch Intern Med 152 (1992): 1093</p><p id="ref_39">39. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Thorgeirsson G, Pyorala K, Miettinen T, Wilhelmsen L, Olsson AG, Wedel "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)." Lancet 344 (1994): 1383-9</p><p id="ref_40">40. Katznelson S "Effect of HMG-CoA reductase inhibitors on chronic allograft rejection." Kidney Int 56 (1999): s117-21</p><p id="ref_41">41. Halkin A, Lossos IS, Mevorach D "HMG-CoA reductase inhibitor-induced impotence." Ann Pharmacother 30 (1996): 192</p><p id="ref_42">42. Shah B,  McAllister A,  Davidson TM "Increased epistaxis with use of ezetimibe / simvastatin." Ann Pharmacother 43 (2009): 1545</p><p id="ref_43">43. Phan T, Mcleod JG, Pollard JD, Peiris O, Rohan A, Halpern JP "Peripheral neuropathy associated with simvastatin." J Neurol Neurosurg Psychiatry 58 (1995): 625-8</p><p id="ref_44">44. Gaist D,  Jeppesen U,  Andersen M,  Garcia Rodriguez LA,  Hallas J,  Sindrup SH "Statins and risk of polyneuropathy: a case-control study." Neurology 58 (2002): 1333-7</p><p id="ref_45">45. Orsi A, Sherman O, Woldeselassie "Simvastatin-associated memory loss." Pharmacotherapy 21 (2001): 767-9</p><p id="ref_46">46. Bjerre LM, LeLorier J "Do statins cause cancer? A meta-analysis of large randomized clinical trials." Am J Med 110 (2001): 716-23</p><p id="ref_47">47. Newman TB, Hulley SB "Carcinogenicity of lipid-lowering drugs." JAMA 275 (1996): 55-60</p><p id="ref_48">48. Duits N, Bos FM "Depressive symptoms and cholesterol-lowering drugs." Lancet 341 (1993): 114</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Vytorin (ezetimibe / simvastatin)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>20 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: antihyperlipidemic combinations</li>
<li>FDA Alerts (8)</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Vytorin &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>High Cholesterol</li>
<li>High Cholesterol, Familial Heterozygous</li>
<li>High Cholesterol, Familial Homozygous</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ezetimibe / simvastatin: oral tablet</i></p><h3>General</h3><p>The more commonly reported adverse effects have included headache, increased ALT, myalgia, upper respiratory tract infection, and diarrhea.</p><h3>Gastrointestinal</h3><p>Ezetimibe-simvastatin: </p><p><b>Common</b> (1% to 10%): Diarrhea</p><p></p><p>Ezetimibe:</p><p><b>Common</b> (1% to 10%): Diarrhea, abdominal pain, nausea</p><p><b>Postmarketing reports</b>: Pancreatitis</p><p></p><p>Simvastatin:</p><p><b>Common</b> (1% to 10%): Constipation, nausea, flatulence, diarrhea, dyspepsia, abdominal pain, pancreatitis, anorexia, vomiting, gastritis</p><p><b>Very rare</b> (less than 0.01%): Protein losing enteropathy<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Simvastatin has been associated with rare cases of severe myopathy and rhabdomyolysis.  This is accompanied by elevations in creatine kinase, myoglobinuria, and proteinuria, as well as renal failure.  Experience with HMG-CoA reductase inhibitors indicates that concomitant use with gemfibrozil, niacin, cyclosporine, or erythromycin may increase the incidence and the severity of musculoskeletal side effects.</p><p></p><p>A case of spontaneous biceps tendon rupture developed in a patient after 4 months of treatment with ezetimibe-simvastatin.  Upon rechallenge 2 months later, the patient developed pain in the contralateral arm overlying the biceps tendon.  Following discontinuation of ezetimibe-simvastatin, pain resolved 2 weeks later.  Inhibition of matrix metalloproteinases has been suggested as the contributing factor in the development of tendon rupture.<sup>[Ref]</sup></p><p>Ezetimibe-simvastatin: </p><p><b>Common</b> (1% to 10%): Myalgia, extremity pain </p><p><b>Very rare</b> (less than 0.01%): Tendon rupture (one case)</p><p><b>Frequency not reported</b>: Back pain </p><p><b>Postmarketing reports</b>: Muscle cramps </p><p></p><p>Ezetimibe:</p><p><b>Common</b> (1% to 10%): Back pain, arthralgia</p><p><b>Postmarketing reports</b>: Myalgia, elevated creatine phosphokinase, rare reports of myopathy/rhabdomyolysis</p><p></p><p>Simvastatin:</p><p><b>Uncommon</b> (0.1% to 1%): Myopathy, rhabdomyolysis </p><p><b>Frequency not reported</b>: Elevations in creatine kinase, dermatomyositis, arthralgia, myalgia<sup>[Ref]</sup></p><h3>Renal</h3><p>Simvastatin:</p><p><b>Frequency not reported</b>: Myoglobinuria, acute renal failure secondary to rhabdomyolysis<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Persistent elevations in liver function tests three times normal values are reported in up to 1.5% of patients on simvastatin in clinical trials.  In one study, this led to the discontinuation of simvastatin in 0.6% of patients.  In other patients, elevations in liver function tests were transient and returned to normal with continued simvastatin therapy.<sup>[Ref]</sup></p><p>Ezetimibe-simvastatin: </p><p><b>Common</b> (1% to 10%): Increased ALT</p><p><b>Frequency not reported</b>: Increased AST</p><p></p><p>Ezetimibe:</p><p><b>Postmarketing reports</b>: Elevations in liver transaminases, hepatitis, cholelithiasis, cholecystitis</p><p></p><p>Simvastatin:</p><p><b>Common</b> (1% to 10%): Elevations in liver function tests</p><p><b>Frequency not reported</b>: Hepatitis (including chronic active hepatitis), cholestatic jaundice, fatty changes in the liver, cirrhosis, fulminant hepatic necrosis </p><p><b>Postmarketing reports</b>: Hepatic failure, jaundice<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Simvastatin:</p><p><b>Frequency not reported</b>: Eczematous, pruritic rash, toxic epidermal necrolysis, photosensitivity, purpura, erythema multiforme, photosensitivity, purpura, alopecia</p><p><b>Postmarketing reports</b>: A variety of skin changes (e.g., nodules, discoloration, dryness of skin/mucous membranes, changes to hair/nails)<sup>[Ref]</sup></p><h3>Immunologic</h3><p>Ezetimibe-simvastatin: </p><p><b>Frequency not reported</b>: Influenza</p><p></p><p>Ezetimibe:</p><p><b>Common</b> (1% to 10%): Viral infection</p><p></p><p>Simvastatin:</p><p><b>Very rare</b> (less than 0.01%): Lupus-like syndrome</p><p><b>Frequency not reported</b>: Positive ANA, ESR increase, polymyalgia rheumatica, vasculitis</p><p></p><p>Statin use: </p><p><b>Rare</b> (0.01% to 0.1%): Immune-mediated necrotizing myopathy (IMNM)<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Ezetimibe-simvastatin: </p><p><b>Common</b> (1% to 10%): Upper respiratory tract infection</p><p><b>Frequency not reported</b>: Interstitial lung disease causing breathing problems including persistent cough and/or shortness of breath or fever</p><p></p><p>Ezetimibe:</p><p><b>Common</b> (1% to 10%): Coughing</p><p><b>Frequency not reported</b>: Sinusitis </p><p></p><p>Simvastatin:</p><p><b>Frequency not reported</b>: Sinusitis, pharyngitis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Simvastatin:</p><p><b>Common</b> (1% to 10%): Angina</p><p><b>Frequency not reported</b>: Atrial fibrillation, edema<sup>[Ref]</sup></p><h3>Endocrine</h3><p>Simvastatin:</p><p><b>Frequency not reported</b>: Gynecomastia, thyroid function abnormalities<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Simvastatin:</p><p><b>Frequency not reported</b>: Erectile dysfunction, impotence, urinary tract infections<sup>[Ref]</sup></p><h3>Hematologic</h3><p>A 65-year-old male with hereditary hemorrhagic telangiectasia (HHT) who had a history of minimal epistaxis began to experience profuse epistaxis 8 to 10 weeks after starting ezetimibe-simvastatin, The patient had been treated with simvastatin 20 mg alone for 9 years without any adverse effects.  Two months after starting combination therapy with ezetimibe-simvastatin he noticed epistaxis that increased from a few drops every other day to profuse bleeding for 20 to 30 minutes daily.  The patient reported initiation of ezetimibe-simvastatin as the only change in his treatment regimen in the past year.  When he stopped ezetimibe-simvastatin, his epistaxis decreased.  After six weeks without ezetimibe-simvastatin, he had only one moderate nose bleed.  Four months later, the patient's hemoglobin was stable.  He then started simvastatin 40 mg monotherapy.  The profound epistaxis returned and the patient discontinued the medication.  It remains unclear whether the patient's accelerated epistaxis was due to the combination therapy or the double dosage of simvastatin.<sup>[Ref]</sup></p><p>Ezetimibe-simvastatin: </p><p><b>Postmarketing reports</b>: Epistaxis (one report), anemia </p><p></p><p>Ezetimibe:</p><p><b>Postmarketing reports</b>: Thrombocytopenia</p><p></p><p>Simvastatin:</p><p><b>Frequency not reported</b>: Hemolytic anemia, thrombocytopenia, leukopenia (possibly manifestations of a hypersensitivity reaction)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria have been reported.  In addition, an apparent hypersensitivity syndrome has been reported rarely that has included one or more of the following features: anaphylaxis, angioedema, lupus erythematous-like syndrome, polymyalgia rheumatica, dermatomyositis, vasculitis, purpura, thrombocytopenia, leukopenia, hemolytic anemia, positive ANA, ESR increase, eosinophilia, arthritis, arthralgia, urticaria, asthenia, photosensitivity, fever, chills, flushing, malaise, dyspnea, toxic epidermal necrolysis, erythema multiforme, including Stevens-Johnson syndrome.<sup>[Ref]</sup></p><p>Ezetimibe:</p><p><b>Postmarketing reports</b>: Angioedema, anaphylaxis, rash, urticaria</p><p></p><p>Simvastatin:</p><p><b>Rare</b> (less than 0.1%): Erythema multiforme, Stevens-Johnson syndrome, anaphylaxis, angioedema, urticaria, fever, chills, flushing, malaise, dyspnea</p><p><b>Postmarketing reports</b>: Hypersensitivity reactions<sup>[Ref]</sup></p><h3>Nervous system</h3><p>A case of memory loss possibly related to simvastatin use has been reported.  The patient developed gradual memory loss following 12 months of simvastatin therapy.  He was switched to pravastatin, and within a month his memory was intact.  Rechallenge with simvastatin was not performed.</p><p></p><p>There have been rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use.  These reports have been generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).<sup>[Ref]</sup></p><p>Ezetimibe-simvastatin: </p><p><b>Common</b> (1% to 10%): Headache</p><p><b>Frequency not reported</b>: Confusion, fatigue</p><p></p><p>Ezetimibe:</p><p><b>Postmarketing reports</b>: Dizziness, paraesthesia</p><p></p><p>Simvastatin:</p><p><b>Frequency not reported</b>: Cranial nerve dysfunction, tremor, vertigo, memory loss, paraesthesias, peripheral neuropathy, peripheral nerve palsy</p><p></p><p>Statins: </p><p><b>Postmarketing reports</b>: Cognitive impairment<sup>[Ref]</sup></p><h3>Ocular</h3><p>Simvastatin:</p><p><b>Frequency not reported</b>: Progression of cataracts, ophthalmoplegia<sup>[Ref]</sup></p><h3>Oncologic</h3><p>Simvastatin:</p><p><b>Frequency not reported</b>: Liver, thyroid, and lung adenomas and carcinomas<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Simvastatin:</p><p><b>Frequency not reported</b>: Depression, suicidal thoughts, delusions, paranoia, agitation, decreased libido, anxiety, insomnia<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Simvastatin: </p><p><b>Frequency not reported</b>: Increases in HbA1c and fasting serum glucose levels</p><h3>Other</h3><p>Ezetimibe: </p><p><b>Frequency not reported</b>: Fatigue, asthenia<sup>[Ref]</sup></p><p id="ref_1">1. Plosker GL, Mctavish D "Simvastatin - a reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia." Drugs 50 (1995): 334-63</p><p id="ref_2">2. Abernethy DR, Greenblatt DJ, Morse DS, Shader RI "Interaction of propoxyphene with diazepam, alprazolam and lorazepam." Br J Clin Pharmacol 19 (1985): 51-7</p><p id="ref_3">3. Chagnon JP, Cerf M "Simvastatin-induced protein-losing enteropathy." Am J Gastroenterol 87 (1992): 257</p><p id="ref_4">4. Simons LA "Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. The Principal Investigators." Clin Cardiol 16 (1993): 317-22</p><p id="ref_5">5. "Product Information. Zocor (simvastatin)." Merck &amp; Co, Inc, West Point, PA. </p><p id="ref_6">6. Walker JF "Simvastatin: the clinical profile." Am J Med 87 (1989): s44-6</p><p id="ref_7">7. "Product Information. Vytorin (ezetimibe-simvastatin)." Merck &amp; Company Inc, West Point, PA. </p><p id="ref_8">8. "Product Information. Zetia (ezetimibe)." Schering-Plough Corporation, Kenilworth, NJ. </p><p id="ref_9">9. Federman DG,  Hussain F,  Walters AB "Fatal rhabdomyolysis caused by lipid-lowering therapy." South Med J 94 (2001): 1023-6</p><p id="ref_10">10. Itakura H,  Vaughn D,  Haller DG,  O'Dwyer PJ "Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer." J Urol 169 (2003): 613</p><p id="ref_11">11. Weise WJ, Possidente CJ "Fatal rhabdomyolysis associated with simvastatin in a renal transplant patient." Am J Med 108 (2000): 351-2</p><p id="ref_12">12. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H "HMG-CoA reductase inhibitors and the risk of fractures." JAMA 283 (2000): 3205-10</p><p id="ref_13">13. Sinzinger H,  Wolfram R,  Peskar BA "Muscular side effects of statins." J Cardiovasc Pharmacol 40 (2002): 163-71</p><p id="ref_14">14. Davidson MH,  Maccubbin D,  Stepanavage M,  Strony J,  Musliner T "Striated muscle safety of ezetimibe / simvastatin (vytorin)." Am J Cardiol 97 (2006): 223-8</p><p id="ref_15">15. Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, Miettinen T, Musliner TA, Olsson AG, Pyorala K, Thorgeirsso "Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the scandinavian simvastatin survival study." Arch Intern Med 156 (1996): 2085-92</p><p id="ref_16">16. Schumacher YO,  Zdebik A,  Huonker M,  Kreisel W "Sildenafil in HIV-related pulmonary hypertension." AIDS 15 (2001): 1747-8</p><p id="ref_17">17. McDonagh J, Winocour P, Walker DJ "Musculoskeletal manifestations during simvastatin therapy." Br J Rheumatol 32 (1993): 647-8</p><p id="ref_18">18. Peces R,  Pobes A "Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem." Nephron 89 (2001): 117-8</p><p id="ref_19">19. Chan MH,  Mak TW,  Chiu RW,  Chow CC,  Chan IH,  Lam CW "Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia." J Clin Endocrinol Metab 86 (2001): 4556-9</p><p id="ref_20">20. Maxa JL,  Melton LB,  Ogu CC,  Sills MN,  Limanni A "Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole." Ann Pharmacother 36 (2002): 820-3</p><p id="ref_21">21. Pullatt RC,  Gadarla MR,  Karas RH,  Alsheikh-Ali AA,  Thompson PD "Tendon rupture associated with simvastatin/ezetimibe therapy." Am J Cardiol 100 (2007): 152-3</p><p id="ref_22">22. Alvarez JM, Rawdanowiz TJ, Goldstein J "Rhadbdomyolysis after coronary artery bypass grafting in a patient receiving simvastatin." J Thorac Cardiovasc Surg 116 (1998): 654-5</p><p id="ref_23">23. "Summaries for patients. Muscle abnormalities in four patients taking statins to treat unfavorable cholesterol levels." Ann Intern Med 137 (2002): I45</p><p id="ref_24">24. Khattak FH, Morris IM, Branford WA "Simvastatin-associated dermatomyositis." Br J Rheumatol 33 (1994): 199</p><p id="ref_25">25. Omar MA,  Wilson JP "FDA adverse event reports on statin-associated rhabdomyolysis." Ann Pharmacother 36 (2002): 288-95</p><p id="ref_26">26. van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996): 403-4</p><p id="ref_27">27. Vanpuijenbroek EP, Dubufvereijken PWG, Spooren PFMJ, Vandoormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996): 403-4</p><p id="ref_28">28. Havranek JM,  Wolfsen AR,  Warnke GA,  Phillips PS "Monotherapy with ezetimibe causing myopathy." Am J Med 119 (2006): 285-6</p><p id="ref_29">29. Chariot P, Abadia R, Agnus D, Danan C, Charpentier C, Gherardi RK "Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome." Am J Med 94 (1993): 109-10</p><p id="ref_30">30. ChoquetKastylevsky G, Kanitakis J, Dumas V, Descotes J, Faure M, Claudy A "Eosinophilic fasciitis and simvastatin." Arch Intern Med 161 (2001): 1456-7</p><p id="ref_31">31. Grundy SM "Can statins cause chronic low-grade myopathy?" Ann Intern Med 137 (2002): 617-8</p><p id="ref_32">32. Yurdakok M, Gurakan B, Ergin H, Kirazli S "Plasma concentrations of granulocyte colony stimulating factor in preterm infants in the first few hours of life." Acta Paediatr 85 (1996): 1389-90</p><p id="ref_33">33. Mauro VF, MacDonald JL "Simvastatin: a review of its pharmacology and clinical use." DICP 25 (1991): 257-64</p><p id="ref_34">34. Nakad A, Bataille L, Hamoir V, Sempoux C, Horsmans Y "Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin." Lancet 353 (1999): 1763-4</p><p id="ref_35">35. Krasovec M, Elsner P, Burg G "Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors." Dermatology 186 (1993): 248-52</p><p id="ref_36">36. Feldmann R, Mainetti C, Saurat JH "Skin lesions due to treatment with simvastatin (Zocor)." Dermatology 186 (1993): 272</p><p id="ref_37">37. Rudski L, Rabinovitch MA, Danoff D "Systemic immune reactions to HMG-CoA reductase inhibitors - Report of 4 cases and review of the literature." Medicine 77 (1998): 378-83</p><p id="ref_38">38. Bannwarth B, Miremont G, Papapietro PM "Lupuslike syndrome associated with simvastatin." Arch Intern Med 152 (1992): 1093</p><p id="ref_39">39. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Thorgeirsson G, Pyorala K, Miettinen T, Wilhelmsen L, Olsson AG, Wedel "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)." Lancet 344 (1994): 1383-9</p><p id="ref_40">40. Katznelson S "Effect of HMG-CoA reductase inhibitors on chronic allograft rejection." Kidney Int 56 (1999): s117-21</p><p id="ref_41">41. Halkin A, Lossos IS, Mevorach D "HMG-CoA reductase inhibitor-induced impotence." Ann Pharmacother 30 (1996): 192</p><p id="ref_42">42. Shah B,  McAllister A,  Davidson TM "Increased epistaxis with use of ezetimibe / simvastatin." Ann Pharmacother 43 (2009): 1545</p><p id="ref_43">43. Phan T, Mcleod JG, Pollard JD, Peiris O, Rohan A, Halpern JP "Peripheral neuropathy associated with simvastatin." J Neurol Neurosurg Psychiatry 58 (1995): 625-8</p><p id="ref_44">44. Gaist D,  Jeppesen U,  Andersen M,  Garcia Rodriguez LA,  Hallas J,  Sindrup SH "Statins and risk of polyneuropathy: a case-control study." Neurology 58 (2002): 1333-7</p><p id="ref_45">45. Orsi A, Sherman O, Woldeselassie "Simvastatin-associated memory loss." Pharmacotherapy 21 (2001): 767-9</p><p id="ref_46">46. Bjerre LM, LeLorier J "Do statins cause cancer? A meta-analysis of large randomized clinical trials." Am J Med 110 (2001): 716-23</p><p id="ref_47">47. Newman TB, Hulley SB "Carcinogenicity of lipid-lowering drugs." JAMA 275 (1996): 55-60</p><p id="ref_48">48. Duits N, Bos FM "Depressive symptoms and cholesterol-lowering drugs." Lancet 341 (1993): 114</p><h2>More about Vytorin (ezetimibe / simvastatin)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>20 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: antihyperlipidemic combinations</li>
<li>FDA Alerts (8)</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Vytorin &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>High Cholesterol</li>
<li>High Cholesterol, Familial Heterozygous</li>
<li>High Cholesterol, Familial Homozygous</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>